Related Experiment Video
Updated: May 19, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition
Rainer Wilcken1, GuoZhen Wang, Frank M Boeckler
1MRC Laboratory of Molecular Biology, Cambridge, United Kingdom.
Abstract:
Aggregation of destabilized mutants of the tumor suppressor p53 is a major route for its loss of activity. In order to assay drugs that inhibit aggregation of p53, we established the basic kinetics of aggregation of its core domain, using the mutant Y220C that has a mutation-induced, druggable cavity. Aggregation monitored by light scattering followed lag kinetics. Electron microscopy revealed the formation of small aggregates that subsequently grew to larger amorphous aggregates. The kinetics of aggregation produced surprising results: progress curves followed either by the binding of Thioflavin T or the fluorescence of the protein at 340 nm fitted well to simple two-step sequential first-order lag kinetics with rate constants k(1) and k(2) that were independent of protein concentration, and not to classical nucleation-growth. We suggest a mechanism of first-order formation of an aggregation competent state as being rate determining followed by rapid polymerization with the higher order kinetics. By measuring the inhibition kinetics of k(1) and k(2), we resolved that the process with the higher rate constant followed that of the lower. Further, there was only partial inhibition of k(1) and k(2), which showed two parallel pathways of aggregation, one via a state that requires unfolding of the protein and the other of partial unfolding with the ligand still bound. Inhibition kinetics of ligands provides a useful tool for probing an aggregation mechanism.
Insights
Drug discovery for tumor suppressor p53 aggregation is crucial. This study reveals novel insights into p53 aggregation kinetics, identifying two parallel pathways and offering a new method for drug screening.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- Destabilized mutants of the tumor suppressor p53 aggregate, leading to loss of function.
- Understanding p53 aggregation is key for developing drugs to inhibit this process.
Purpose of the Study:
- To establish the basic kinetics of p53 core domain aggregation using the Y220C mutant.
- To investigate potential drug candidates that inhibit p53 aggregation.
Main Methods:
- Monitoring aggregation kinetics using light scattering and Thioflavin T binding.
- Analyzing aggregate morphology via electron microscopy.
- Studying inhibition kinetics of aggregation pathways.
Main Results:
- Aggregation followed a two-step sequential first-order lag kinetics, not classical nucleation-growth.
- Two parallel aggregation pathways were identified: one requiring unfolding, the other partial unfolding with ligand bound.
- Inhibition kinetics revealed partial inhibition of both pathways, suggesting complex drug interactions.
Conclusions:
- The identified aggregation mechanism provides a basis for developing targeted drugs against p53 aggregation.
- Ligand inhibition kinetics serve as a valuable tool for dissecting complex protein aggregation mechanisms.
- This research offers a novel approach for assaying drugs that inhibit p53 aggregation.
Related Concept Videos
Abnormal Proliferation
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Negative Regulator Molecules
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle

